This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

LUDWIG VON SALLMANN, MD; PATRICIA GRIMES, BA; ELEANOR COLLINS

Arch Ophthalmol. 1963;70(4):522-530.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

Among the recently developed inhibitors of cholesterol biosynthesis, the compound, p-(β-diethylaminoethoxy) phenyl-1-(p-tolyl)-2-(p-chlorophenyl) ethanol, or triparanol (Mer-29), has received prominent attention from the medical profession because of its potent effect in reducing elevated blood cholesterol levels and the relative safety of its use. The basic physiological and biochemical mechanisms of its action, together with the results of clinical observations on treated patients, were discussed in a conference of representatives from leading medical centers in December, 1959.¹ At that time no complications had been observed in acute and chronic toxicity studies, except for a decrease of the lipid content in the fascicular and reticular zones of the adrenal gland. In April, 1961, Achor, Winkelmann, and Perry² published a preliminary report of thinning and loss of hair and ichthyotic changes of the skin in two patients with hypercholesteremia who had received triparanol for several months. . . . [Full Text PDF of this Article]

Author Affiliations
Bethesda, Md

From the Ophthalmology Branch, National Institute of Neurological Diseases and Blindness, National Institutes of Health, Public Health Service, US Department of Health, Education and Welfare.

Footnotes
Submitted for publication April 8, 1963.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?